Collaborate with usWhat’s new?
Insights

Defining the future of Clinical Care.

Our industry-leading approach is paving the way for personalized, patient-centric treatments.

Publication

Six Month Outcomes from Clickotine®: A Digital Therapeutic™ Program for Smoking Cessation

Presented at the Society for Research on Nicotine and Tobacco, March 2017.

Authors:

Iacoviello et al.

Related subjects:

Posters & Presentations

Contact:

To request information regarding this poster, please contact medicalaffairs@clicktherapeutics.com

Discover our products

CT-152

CT-152

Rejoyn

Indication

Major Depressive Disorder (MDD)

Collaborator

Otsuka Pharmaceutical

Phase

Launch
AspyreRx

AspyreRx

AspyreRx™

Indication

Type 2 Diabetes

Collaborator

Phase

FDA Authorized
CT-132

CT-132

Indication

Episodic Migraine

Collaborator

Phase

FDA Authorized
CT-155

CT-155

Indication

Schizophrenia

Collaborator

Phase

Phase 3: Pivotal/Reg
CT-156

CT-156

Indication

Schizophrenia

Collaborator

Phase

Phase 2: Dev/Pilot
CT-102

CT-102

Indication

Opioid Use Disorder (OUD)

Collaborator

Phase

Phase 2: Dev/Pilot
CT-133

CT-133

Indication

Multiple Sclerosis (MS)

Collaborator

Phase

Phase 1: Discovery
CT-171

CT-171

Indication

Atopic Dermatitis

Collaborator

Phase

Phase 1: Discovery
CT-181

CT-181

Indication

Obesity

Collaborator

Phase

Phase 1: Discovery
CT-191

CT-191

Indication

Oncology

Collaborator

Phase

Phase 1: Discovery
CT-141

CT-141

Clickadian™

Indication

Insomnia

Collaborator

Phase

Phase 1: Discovery
CT-111

CT-111

Clickheart™

Indication

Acute Coronary Syndrome

Collaborator

Phase

Phase 1: Discovery
CT-152

CT-152

Rejoyn

Indication

Major Depressive Disorder (MDD)

Collaborator

Otsuka Pharmaceutical

Phase

Launch
AspyreRx

AspyreRx

AspyreRx™

Indication

Type 2 Diabetes

Collaborator

Phase

FDA Authorized
CT-132

CT-132

Indication

Episodic Migraine

Collaborator

Phase

FDA Authorized
CT-155

CT-155

Indication

Schizophrenia

Collaborator

Phase

Phase 3: Pivotal/Reg
CT-156

CT-156

Indication

Schizophrenia

Collaborator

Phase

Phase 2: Dev/Pilot
CT-102

CT-102

Indication

Opioid Use Disorder (OUD)

Collaborator

Phase

Phase 2: Dev/Pilot
CT-133

CT-133

Indication

Multiple Sclerosis (MS)

Collaborator

Phase

Phase 1: Discovery
CT-171

CT-171

Indication

Atopic Dermatitis

Collaborator

Phase

Phase 1: Discovery
CT-181

CT-181

Indication

Obesity

Collaborator

Phase

Phase 1: Discovery
CT-191

CT-191

Indication

Oncology

Collaborator

Phase

Phase 1: Discovery
CT-141

CT-141

Clickadian™

Indication

Insomnia

Collaborator

Phase

Phase 1: Discovery
CT-111

CT-111

Clickheart™

Indication

Acute Coronary Syndrome

Collaborator

Phase

Phase 1: Discovery

Stay up to date with news and updates